Research progress on the efficacy and safety of PARP inhibitors in mCRPC / 中华泌尿外科杂志
Chinese Journal of Urology
; (12): 551-554, 2023.
Article
em Zh
| WPRIM
| ID: wpr-994083
Biblioteca responsável:
WPRO
ABSTRACT
Poly ADP-ribose polymerase (PARP) inhibitors are novel agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years, and a variety of PARP inhibitors have been reported with clinical evidence for the beneficial. Although these drugs are actually of attributes with pharmacological similarities, due to the discrepancies in the molecular structure and pharmacodynamics, the respective efficacy and safety from clinical circumstances are quite varied. While it comes to the best clinical determination, the optimization for regimen is important on the basis of clinical exhaustiveness for the reports, in addition the laboratory examination for mCRPC, and either the tumorous genetic benchmark are necessarily being calculated.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Urology
Ano de publicação:
2023
Tipo de documento:
Article